Skip Navigation

Center for Cancer Genome Discovery

  • Matthew Meyerson, MD, PhD, and William Hahn, MD, PhD
  • The mission of the Center for Cancer Genome Discovery (CCGD) is to advance precision cancer medicine by developing new technologies for the analysis of cancer genomes and to provide basic, translational, and clinical investigators with access to these technologies.

    The three main components of our mission are:

    • Technology Development: To develop new technologies for the analysis of cancer genomes
    • Collaborative Research: To provide access to these genomic technologies to basic, translational, and clinical investigators at Dana-Farber and beyond
    • Translation: To translate technologies to the clinical setting

    The Center for Cancer Genome Discovery is the research and development group within the Precision Cancer Medicine effort at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Boston Children's Hospital. As part of that effort, CCGD continually evaluates and develops new sequencing assays and technologies — both for research and clinical use — which allows us to assist investigators pursuing novel questions and new techniques.

    Our focus is discovery of genomic alterations in human cancer and evaluation of their clinical significance for informing diagnosis and treatment. We use an Illumina next-generation sequencing platform to detect the full range of genomic alterations, including:

    • Single nucleotide variants
    • Insertions and deletions
    • Chromosomal rearrangements: translocations, inversions, duplications
    • Copy number changes
    • Expression changes
    • Allele-specific expression
    • Detection and quantification of gene fusion

    An integral aspect of the Center's mission is working toward more effective clinical trial designs, in which patients with similar genetically defined cancers will receive drugs designed to target specific genetic aberrations. In addition to the main areas indicated above, CCGD is available to assist collaborators with funding (e.g., grant submissions), experimental design, and coordination of each project through the appropriate channels.

    Our research and development group continually evaluates and develops next-generation sequencing technologies for both research and clinical use. From our inception, we have collaborated with research investigators to develop new genome discovery tools, and we welcome investigators and clinicians to contact us about new avenues of research we can help facilitate. We can provide a host of services that include project design, sequencing library construction, custom design and validation of hybrid capture gene panels for targeted sequencing, and bioinformatic analysis.

    Our Services

    CCGD can provide collaborators with comprehensive services that include personal consultation on the type of sequencing most suitable for project needs, preparation of sequencing libraries, and custom bait set design for targeted sequencing. Additionally, sequencing libraries prepared by CCGD are provided with bioinformatic analysis. Read our full listing of services.